Nutcracker Therapeutics is an early stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on our novel ACORN (Automation COntroled RNA) microfluidic based manufacturing system.
ACORN is a fully automated, software-controlled microfluidics platform. Our advanced technology-driven approach to therapeutics manufacturing addresses significant challenges associated with production and scale-up of therapeutic products. Automation and microfluidics deliver significantly reduced production cycle times, increased process control, efficiency and reproducibility while greatly reducing manual manipulations, risks of contamination and costly facilities. Through the introduction of breakthrough therapeutic micro factories, Nutcracker is poised to deliver on our mission to significantly improve patient’s lives.
ACORN is a fully automated, software-controlled microfluidics platform. Our advanced technology-driven approach to therapeutics manufacturing addresses significant challenges associated with production and scale-up of therapeutic products. Automation and microfluidics deliver significantly reduced production cycle times, increased process control, efficiency and reproducibility while greatly reducing manual manipulations, risks of contamination and costly facilities. Through the introduction of breakthrough therapeutic micro factories, Nutcracker is poised to deliver on our mission to significantly improve patient’s lives.
Location: United States, California, Emeryville
Employees: 51-200
Total raised: $227M
Founded date: 2018
Investors 5
| Date | Name | Website |
| 08.05.2022 | ND CAPITAL | nd.capital |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | BlueBird V... | bluebirdvc... |
| 23.10.2022 | AE Investm... | aeinvestme... |
| - | Altitude L... | altitudels... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.03.2022 | Series C | $167M | ARCH Ventu... |
| 23.09.2020 | Series B | $60M | ARCH Ventu... |
Mentions in press and media 8
| Date | Title | Description |
| 15.03.2022 | Nutcracker Therapeutics raises $167M Series C | Nutcracker Therapeutics has raised $167 million in a round led by Arch Venture Partners. The Emeryville, Calif.-based company is developing mRNA therapeutic drug products. Nutcracker was valued at $954.5 million in September 2021, according... |
| 14.03.2022 | GMP-in-a-box company with Bob Nelsen backing lands $167M to develop its own cancer drugs | For the fourth time in as many weeks, a company focused on portable drug manufacturing is making noise. This time, Nutcracker Therapeutics has brought in $167 million in a Series C round led by ARCH Venture Partners. The company will use th... |
| 14.03.2022 | Nutcracker snags $167M series C to develop 'push-button' RNA manufacturing, signs on former Gilead CFO | Nutcracker Therapeutics wants to create mRNA medicines with the push of a button, a tough nut to crack that is now backed by Arch Venture Partners and others with a $167 million series C. The Emeryville, California, biotech will use the pro... |
| 14.03.2022 | Nutcracker Therapeutics Raises $167M in Series C | EMERYVILLE, CA, Nutcracker Therapeutics, a biotech company developing RNA therapeutics, announced it has raised $167M in Series C financing led by ARCH Venture Partners. >> Click here for more funding data on Nutcracker Therapeutic... |
| 14.03.2022 | Nutcracker Therapeutics with Bob Nelsen backing lands $167M to develop its own cancer drugs | - |
| 25.09.2020 | Nutcracker Therapeutics Raises $60M in Series B Financing | Nutcracker Therapeutics, Inc., an Emeryville, Calif.-based company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, raised $60m in Series B financing. The round was led by Arch Venture Par... |
| 24.09.2020 | Nutcracker Therapeutics Inks $60M Series B | EMERYVILLE, CA, Nutcracker Therapeutic has raised $60 million in Series B financing led by ARCH Venture Partners. >> Click here for more funding data on Nutcracker Therapeutics >> To export Nutcracker Therapeutics funding da... |
| 23.09.2020 | Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform |